Short answer: cholecalciferol (vitamin D3) is the most widely used and most studied form of vitamin D replacement in the world. Calcifediol is 25-hydroxyvitamin D itself, the compound the blood test measures: because it "skips" the liver step and is absorbed more completely, it raises 25(OH)D faster and at much lower doses, roughly 2 to 5 times more potent depending on the study (Quesada-Gomez & Bouillon, Osteoporos Int 2018; Bouden et al., Eur J Clin Nutr 2025). That does not make it "better for everyone": because it is more potent, the doses are not interchangeable, and excess shows up sooner. Today it makes the most sense in specific situations, such as intestinal malabsorption, bariatric surgery, liver disease, obesity, or when a deficiency needs to be corrected quickly (Jodar et al., Eur J Nutr 2023; Cesareo et al., Nutrients 2019; Koga et al., Arch Endocrinol Metab 2025). The choice is individual.
What each one is
The vitamin D we make in the skin with sunlight, or take in by mouth, is cholecalciferol (D3). It is not yet active: first the liver adds a hydroxyl group at position 25, forming 25-hydroxyvitamin D [25(OH)D], also called calcifediol or calcidiol. This is the form that circulates in the largest amount and the one the lab measures in a "vitamin D" test. Then, mainly in the kidney, it is converted into calcitriol, the active hormone (Bouillon & Quesada-Gomez, J Steroid Biochem Mol Biol 2023; Cianferotti et al., Endocrine 2015).
In other words: taking calcifediol means taking the very metabolite the test measures, without relying on conversion in the liver. It is not the same as taking calcitriol or alfacalcidol, the active forms, which have their own indications (such as advanced kidney disease and hypoparathyroidism) and are not used routinely to correct a common deficiency, because of the risk of high calcium in the blood and urine (Cesareo et al., Nutrients 2018; Cianferotti et al., Endocrine 2015).
Side-by-side comparison
| Feature | Cholecalciferol (D3) | Calcifediol (25(OH)D) |
|---|---|---|
| Liver step | Must be converted into 25(OH)D | Already is 25(OH)D |
| Intestinal absorption | Depends on fat, bile and the lymphatic route (chylomicrons) | More hydrophilic, absorbed almost completely via the portal vein |
| Speed of 25(OH)D rise | Gradual (weeks to months) | Fast (days to a few weeks) |
| Potency per microgram | Reference (1×) | About 2 to 5× in studies; average of 3.2× at physiological doses |
| Dose-response curve | Flattens when the starting level is already higher | More linear and predictable |
| Storage in adipose tissue | Greater | Smaller |
| Decline after stopping | Slow | Faster |
| Body of evidence | Decades of use and most of the large trials | Smaller, growing, mostly in Europe |
Table sources: reviews by Quesada-Gomez & Bouillon and by Jodar et al., the meta-analysis by Bouden et al., and the trials cited below (Quesada-Gomez & Bouillon, Osteoporos Int 2018; Jodar et al., Eur J Nutr 2023; Bouden et al., Eur J Clin Nutr 2025).
Why calcifediol raises the level faster
1. It does not depend on the liver
Converting D3 into 25(OH)D depends on the enzyme 25-hydroxylase (mainly CYP2R1). The activity of this step varies from person to person because of genetic differences, and it may be reduced in liver disease and in obesity. Calcifediol enters after this step, which helps explain the more uniform response across people (Jodar et al., Eur J Nutr 2023; Pérez-Castrillón et al., Nutrients 2022).
2. It is absorbed more completely
Cholecalciferol is highly fat-soluble: to be absorbed, it needs fat and bile in the meal and travels through the lymphatic route inside chylomicrons. Calcifediol, with one extra hydroxyl group, is more polar and goes straight into the circulation via the portal vein. That is why, in people with fat malabsorption, calcifediol absorption tends to remain practically preserved, while D3 absorption drops considerably (Quesada-Gomez & Bouillon, Osteoporos Int 2018; Bouillon & Quesada-Gomez, J Steroid Biochem Mol Biol 2023).
3. It gets less "trapped" in body fat
Because it is more hydrophilic, calcifediol accumulates less in adipose tissue, one of the reasons why people with obesity usually need higher doses of D3 to reach the same level (Jodar et al., Eur J Nutr 2023; Holick et al., J Clin Endocrinol Metab 2011).
What the studies show, in numbers
The two forms have been compared head to head in several randomized trials. The main results:
| Study | Participants | Doses compared | Main result |
|---|---|---|---|
| Bischoff-Ferrari et al., 2012 | 20 postmenopausal women | 20 µg/day of each, for 4 months | Mean 25(OH)D of 69.5 ng/mL with calcifediol vs 31.0 ng/mL with D3; no hypercalcemia |
| Cashman et al., 2012 | 56 adults aged ≥ 50, in winter | 7 or 20 µg/day of calcifediol vs 20 µg/day of D3, 10 weeks | Each microgram of calcifediol yielded about 4 to 5 times more 25(OH)D |
| Jetter et al., 2014 | 35 women aged 50 to 70 | Daily, weekly or single dose | Calcifediol about 2 to 3× more potent; all exceeded 30 ng/mL, on average in 16.8 days, vs 70% in 68.4 days with D3 |
| Shieh et al., 2017 | 35 adults with 25(OH)D < 20 ng/mL | 20 µg/day of calcifediol vs 60 µg/day (2,400 IU) of D3, 16 weeks | At 4 weeks, 87.5% vs 23.1% reached ≥ 30 ng/mL |
| Vaes et al., 2018 | 59 people aged ≥ 65 | 5, 10 or 15 µg/day of calcifediol vs 20 µg/day of D3, 24 weeks | 10 and 15 µg of calcifediol exceeded 75 nmol/L at 8 and 4 weeks; D3 came close to 70 nmol/L at 16 weeks |
| Graeff-Armas et al., 2020 | 91 adults, mean age 63 | 10, 15 or 20 µg/day of calcifediol vs 20 µg/day of D3, 6 months | About 3× more effective per microgram; 75 nmol/L in 7 to 10 days vs 40 days |
| Pérez-Castrillón et al., 2021 and 2023 | 303 postmenopausal women with 25(OH)D < 20 ng/mL | Calcifediol 0.266 mg/month vs D3 25,000 IU/month, 12 months | At 4 months, 35.0% vs 8.2% above 30 ng/mL; at 12 months, similar mean levels (23.9 vs 22.4 ng/mL); after calcifediol was stopped, the level returned to baseline |
These numbers come from the trials themselves (Bischoff-Ferrari et al., J Bone Miner Res 2012; Cashman et al., Am J Clin Nutr 2012; Jetter et al., Bone 2014; Shieh et al., J Clin Endocrinol Metab 2017; Vaes et al., Clin Nutr 2018; Graeff-Armas et al., J Nutr 2020; Pérez-Castrillón et al., J Bone Miner Res 2021; Pérez-Castrillón et al., J Bone Miner Res 2023). In a review of nine trials using physiological doses (up to 25 µg/day), each microgram of D3 raised 25(OH)D by about 1.5 nmol/L, vs 4.8 nmol/L per microgram of calcifediol, that is, an average potency 3.2 times higher (Quesada-Gomez & Bouillon, Osteoporos Int 2018).
The most recent meta-analysis pooled 17 studies and 1,575 participants: in 12 trials calcifediol raised 25(OH)D more; in 2 the two forms were equivalent; and in 3 D3 was more effective, which shows that dose, frequency and participant profile change the result (Bouden et al., Eur J Clin Nutr 2025).
The doses are not equivalent
This is the most important point for safety. One microgram of calcifediol is not equivalent to one microgram of D3. In Spain, where calcifediol has been used for decades, a study drew attention to the habit of prescribing calcifediol at the same dose as D3: with 20 µg/day for 12 months, 25(OH)D reached 188 nmol/L with calcifediol, vs 86 nmol/L with D3; with 266 µg per week, 233 nmol/L (Navarro-Valverde et al., J Steroid Biochem Mol Biol 2016). In 2019, the Spanish medicines agency (AEMPS) published a warning about serious cases of hypercalcemia associated with vitamin D doses and frequencies above those recommended, including calcifediol.
In Brazil, a case report from Unifesp (Federal University of São Paulo) showed the other side of the coin: in a patient with cirrhosis, obesity and osteoporosis who was not reaching the target with D3, calcifediol corrected the level within one month, but the dose of 20 µg/day pushed 25(OH)D above 80 ng/mL, requiring a pause and an adjustment to a much lower dose (Koga et al., Arch Endocrinol Metab 2025). The authors stress that the dose must be individualized and monitored with blood tests.
When calcifediol may make sense
European reviews and position statements point to scenarios in which the pharmacological advantages of calcifediol carry more weight (Jodar et al., Eur J Nutr 2023; Cesareo et al., Nutrients 2018; Cesareo et al., Nutrients 2019; Koga et al., Arch Endocrinol Metab 2025):
- Intestinal malabsorption: celiac disease, Crohn's disease, pancreatic insufficiency, cystic fibrosis, short bowel syndrome.
- After bariatric surgery, especially with techniques that reduce fat absorption.
- Liver disease, in which 25-hydroxylation may be impaired.
- Obesity, because of less sequestration in adipose tissue.
- Use of medications that speed up vitamin D metabolism in the liver (some anticonvulsants, corticosteroids and antiretrovirals).
- When a deficiency needs to be corrected quickly, at a physician's discretion.
In chronic kidney disease, the reasoning is different: the main problem usually lies in the kidney step. Even so, an extended-release form of calcifediol was studied in people with stage 3 and 4 kidney disease and secondary hyperparathyroidism: it normalized 25(OH)D in more than 95% of participants and lowered PTH, with little effect on calcium and phosphorus (Sprague et al., Am J Nephrol 2016). This is a specific indication, managed by nephrology.
When cholecalciferol remains the natural choice
For most people with a common deficiency, D3 remains the foundation: it has a much longer track record, more long-term studies, low cost, and it was the form used in the large osteoporosis trials (Bouillon & Quesada-Gomez, J Steroid Biochem Mol Biol 2023; Sosa Henríquez et al., Nutrients 2020). Because D3 has a larger "reserve" and declines more slowly, it also allows spaced-out regimens with more stable levels. In short, the authors of the main reviews describe calcifediol as a useful alternative, not as a universal substitute (Quesada-Gomez & Bouillon, Osteoporos Int 2018; Cianferotti et al., Endocrine 2015).
Safety: what to watch for
At the doses studied, the trials did not report a relevant safety difference between the two forms, and cases of hypercalcemia were rare (Pérez-Castrillón et al., Nutrients 2022; Minisola et al., Osteoporos Int 2017; Bouden et al., Eur J Clin Nutr 2025). The risk appears with high doses over long periods, almost always because of dosing errors or self-medication. Signs of vitamin D excess come from high calcium: nausea, vomiting, excessive thirst and urination, weakness, confusion and, over time, kidney stones and kidney damage (Marcinowska-Suchowierska, Front Endocrinol 2018).
- In Brazil, the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology (SBPC) consider a 25(OH)D above 20 ng/mL adequate for the general population and between 30 and 60 ng/mL for risk groups, such as older adults, pregnant women and people with osteoporosis; above 100 ng/mL there is a risk of toxicity (Moreira et al., Arch Endocrinol Metab 2020).
- Going beyond 60 ng/mL has not shown additional benefit. In an analysis of 2,303 postmenopausal women, standardized levels ≥ 60 ng/mL were associated with a higher chance of two or more falls (an observational association, which does not prove cause) (Binkley et al., Osteoporos Int 2025).
- Because calcifediol rises and falls faster, monitoring with blood tests tends to be closer. Spanish and Italian guidelines cited in the Brazilian case report suggest rechecking 25(OH)D at about 12 weeks (Koga et al., Arch Endocrinol Metab 2025).
What about Brazil?
According to a publication in Archives of Endocrinology and Metabolism, calcifediol has been available in Brazil as a supplement since 2022, as a 10 µg tablet (Koga et al., Arch Endocrinol Metab 2025). In Europe, use as a supplement in the healthy population has been limited to up to 10 µg per day in adults; higher therapeutic doses remain under medical supervision and are adjusted according to the 25(OH)D level, the underlying condition and the person's other health conditions (Jodar et al., Eur J Nutr 2023). Vitamin D testing does not need to be done routinely in healthy adults; it is most useful in risk groups and to monitor replacement (Demay et al., J Clin Endocrinol Metab 2024; Pludowski et al., Nutrients 2022).
In summary
- Calcifediol is 25(OH)D itself, the form measured in the blood test; cholecalciferol (D3) needs to be converted in the liver.
- Calcifediol raises the level faster and at lower doses: roughly 2 to 5 times more potent, depending on the study.
- The doses are not equivalent. Switching one form for the other at the same dose can lead to excess.
- It makes the most sense in malabsorption, after bariatric surgery, in liver disease, in obesity or when speed is needed.
- For most people, D3 remains the foundation, with decades of experience and low cost.
- In any case, the decision and the monitoring with blood tests are individual.
Frequently asked questions
Is calcifediol the same as vitamin D?
It is a form of vitamin D: calcifediol is 25-hydroxyvitamin D, the compound the liver makes from cholecalciferol (D3) and that the blood test measures. It is not the active form (calcitriol).
Is calcifediol better than vitamin D3?
It raises the level faster and at lower doses, but that does not make it better for everyone. For most people D3 does the job, with more long-term studies. Calcifediol has an advantage in situations such as malabsorption, after bariatric surgery, liver disease and obesity, always with monitoring.
Can I switch from vitamin D3 to calcifediol at the same dose?
No. The doses are not equivalent: calcifediol is several times more potent per microgram. Using the same dose can raise 25(OH)D too much. Any switch should be guided by a physician, with a follow-up blood test.
How long does calcifediol take to show up in the blood test?
In studies, 25(OH)D rises meaningfully within days to a few weeks; with D3, within weeks to months. In one trial, all participants on calcifediol exceeded 30 ng/mL, on average in 16.8 days, vs 68.4 days with D3.
Is calcifediol useful after bariatric surgery?
It is one of the scenarios in which it is most often mentioned, because calcifediol absorption depends less on dietary fat and bile. The decision, the dose and the follow-up blood tests are up to the team caring for the person.
Does the site's vitamin D calculator work for calcifediol?
No. The calculator was designed for cholecalciferol (D3). Because calcifediol is more potent, applying the same result to it would give an excessive dose.
What is the ideal vitamin D level in the blood test?
According to the Brazilian position statement (SBEM and SBPC), above 20 ng/mL for the general population and between 30 and 60 ng/mL for risk groups. Above 100 ng/mL there is a risk of toxicity.
References
- Quesada-Gomez JM, Bouillon R. Is calcifediol better than cholecalciferol for vitamin D supplementation?. Osteoporos Int. 2018;29(8):1697-1711. doi:10.1007/s00198-018-4520-y
- Jodar E, Campusano C, de Jongh RT, et al. Calcifediol: a review of its pharmacological characteristics and clinical use in correcting vitamin D deficiency. Eur J Nutr. 2023;62(4):1579-1597. doi:10.1007/s00394-023-03103-1
- Bouillon R, Quesada Gomez JM. Comparison of calcifediol with vitamin D for prevention or cure of vitamin D deficiency. J Steroid Biochem Mol Biol. 2023;228:106248. doi:10.1016/j.jsbmb.2023.106248
- Bouden S, Ben Messaoud M, Saidane O, et al. Effect of cholecalciferol versus calcifediol on serum 25(OH)D concentrations: a systematic review with meta-analysis. Eur J Clin Nutr. 2025;79(4):296-305. doi:10.1038/s41430-024-01520-x
- Pérez-Castrillón JL, Dueñas-Laita A, Brandi ML, et al. Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial. J Bone Miner Res. 2021;36(10):1967-1978. doi:10.1002/jbmr.4387
- Pérez-Castrillón JL, Dueñas-Laita A, Gómez-Alonso C, et al. Long-Term Treatment and Effect of Discontinuation of Calcifediol in Postmenopausal Women with Vitamin D Deficiency: A Randomized Trial. J Bone Miner Res. 2023;38(4):471-479. doi:10.1002/jbmr.4776
- Jetter A, Egli A, Dawson-Hughes B, et al. Pharmacokinetics of oral vitamin D3 and calcifediol. Bone. 2014;59:14-19. doi:10.1016/j.bone.2013.10.014
- Bischoff-Ferrari HA, Dawson-Hughes B, Stöcklin E, et al. Oral supplementation with 25(OH)D3 versus vitamin D3: Effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. J Bone Miner Res. 2012;27(1):160-169. doi:10.1002/jbmr.551
- Cashman KD, Seamans KM, Lucey AJ, et al. Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults. Am J Clin Nutr. 2012;95(6):1350-1356. doi:10.3945/ajcn.111.031427
- Shieh A, Ma C, Chun RF, et al. Effects of Cholecalciferol vs Calcifediol on Total and Free 25-Hydroxyvitamin D and Parathyroid Hormone. J Clin Endocrinol Metab. 2017;102(4):1133-1140. doi:10.1210/jc.2016-3919
- Vaes AM, Tieland M, de Regt MF, et al. Dose–response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults. Clin Nutr. 2018;37(3):808-814. doi:10.1016/j.clnu.2017.03.029
- Graeff-Armas LA, Bendik I, Kunz I, et al. Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults. J Nutr. 2020;150(1):73-81. doi:10.1093/jn/nxz209
- Navarro-Valverde C, Sosa-Henríquez M, Alhambra-Expósito MR, et al. Vitamin D3 and calcidiol are not equipotent. J Steroid Biochem Mol Biol. 2016;164:205-208. doi:10.1016/j.jsbmb.2016.01.014
- Minisola S, Cianferotti L, Biondi P, et al. Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens. Osteoporos Int. 2017;28(11):3239-3249. doi:10.1007/s00198-017-4180-3
- Pérez-Castrillon JL, Usategui-Martín R, Pludowski P. Treatment of Vitamin D Deficiency with Calcifediol: Efficacy and Safety Profile and Predictability of Efficacy. Nutrients. 2022;14(9):1943. doi:10.3390/nu14091943
- Sosa Henríquez M, Gómez de Tejada Romero MJ. Cholecalciferol or Calcifediol in the Management of Vitamin D Deficiency. Nutrients. 2020;12(6):1617. doi:10.3390/nu12061617
- Quesada-Gomez JM, Bouillon R. Calcifediol Cornerstone of the Vitamin D Endocrine System. Nutrients. 2023;15(10):2290. doi:10.3390/nu15102290
- Cesareo R, Attanasio R, Caputo M, et al. Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults. Nutrients. 2018;10(5):546. doi:10.3390/nu10050546
- Cesareo R, Falchetti A, Attanasio R, et al. Hypovitaminosis D: Is It Time to Consider the Use of Calcifediol?. Nutrients. 2019;11(5):1016. doi:10.3390/nu11051016
- Cianferotti L, Cricelli C, Kanis JA, et al. The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Endocrine. 2015;50(1):12-26. doi:10.1007/s12020-015-0606-x
- Pludowski P, Takacs I, Boyanov M, et al. Clinical Practice in the Prevention, Diagnosis and Treatment of Vitamin D Deficiency: A Central and Eastern European Expert Consensus Statement. Nutrients. 2022;14(7):1483. doi:10.3390/nu14071483
- Sprague SM, Crawford PW, Melnick JZ, et al. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol. 2016;44(4):316-325. doi:10.1159/000450766
- Koga GKC, Maeda SS, Lazaretti-Castro M. Rapid and dose-dependent increase of 25(OH)D levels after calcifediol supplementation in a woman with obesity, chronic liver disease, and osteoporosis. Arch Endocrinol Metab. 2025;69(6):1-6. doi:10.20945/2359-4292-2024-0428
- Moreira CA, Ferreira CEdS, Madeira M, et al. Reference values of 25-hydroxyvitamin D revisited: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC). Arch Endocrinol Metab. 2020. doi:10.20945/2359-3997000000258
- Binkley N, Sempos CT, Borchardt G, et al. Association of standardized serum 25-hydroxyvitamin D with falls in post-menopausal women. Osteoporos Int. 2025;36(2):255-264. doi:10.1007/s00198-024-07310-2
- Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930. doi:10.1210/jc.2011-0385
- Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024;109(8):1907-1947. doi:10.1210/clinem/dgae290
- Marcinowska-Suchowierska E, Kupisz-Urbańska M, Łukaszkiewicz J, et al. Vitamin D Toxicity–A Clinical Perspective. Front Endocrinol. 2018;9:550. doi:10.3389/fendo.2018.00550
- van Groningen L, Opdenoordt S, van Sorge A, et al. Cholecalciferol loading dose guideline for vitamin D-deficient adults. Eur J Endocrinol. 2010;162(4):805-811. doi:10.1530/EJE-09-0932
Read also
- Vitamin D calculator (cholecalciferol)Estimate of D3 replacement based on weight and current level
- All toolsCalculators and scales reviewed by a physician
- Vitamin D and obesity (in Portuguese)What studies show about the relationship between the two
Important: This content is strictly educational and must never be used for self-diagnosis or self-treatment. It does not replace a consultation with a qualified health professional. Responsibility for the use of the information presented here lies entirely with the reader.
I declare, transparently, that I have no conflict of interest with any pharmaceutical company that may be mentioned. When I cite brand names or patented products, I do so only to make medical knowledge easier for the general public to understand.
All content on my website and social media is meant to inform, educate and clarify — always free of charge.
No information shared here should be used as the sole basis for assessment, diagnosis or treatment decisions without proper professional guidance. Every person is unique and must be assessed individually. Misuse of this information without professional follow-up may pose serious health risks.
Physician (CRM-SC 32925 | CRM-BA 39586, Brazil). Sees patients by video consultation in Brazil and abroad. This content is educational, reviewed against the cited references, and does not replace a consultation.
Want your case reviewed carefully?
Video consultations in Portuguese or Spanish, for patients in Brazil and abroad.
How video consultations workReviewed on October 31, 2026 by Dr. Diegomaier Nunes Neri — CRM-SC 32925 | CRM-BA 39586 (Brazil).